| DC Field | Value | Language |
|---|
| dc.contributor.author | Andri Prasetiyo | - |
| dc.contributor.author | Shirly Kumala | - |
| dc.contributor.author | Esti Mumpuni | - |
| dc.contributor.author | Raymond R. Tjandrawinata | - |
| dc.date.accessioned | 2022-05-12T11:13:29Z | - |
| dc.date.available | 2022-05-12T11:13:29Z | - |
| dc.date.issued | 2022 | - |
| dc.identifier.citation | Validation of structural-based virtual screening protocols with the PDB Code 3G0B and prediction of the activity of Tinospora crispa compounds as inhibitors of dipeptidyl-peptidase-IV / Andri Prasetiyo [et al.] // Research Results in Pharmacology. - 2022. - Vol.8, №1.-P. 95-102. - Doi: 10.3897/rrpharmacology.8.76237. | ru |
| dc.identifier.uri | http://dspace.bsu.edu.ru/handle/123456789/46691 | - |
| dc.description.abstract | Brotowali (Tinospora crispa) has been traditionally used as an antidiabetic drug. DPP-IV inhibitor as an antidiabetic will increase insulin secretion. It indirectly escalates incretin hormones, such as Glucagon-Like peptide-1 (GLP-1) which depends on glucose. This study predicts potential compounds from the Brotowali plants, such as DPP-IV inhibitors, using the Molegro Virtual Docker (MVD) | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | pharmacology | ru |
| dc.subject | antidiabetic | ru |
| dc.subject | DPP-IV inhibitors | ru |
| dc.subject | Tinospora crispa | ru |
| dc.subject | validation | ru |
| dc.subject | Molegro Virtual Docker | ru |
| dc.title | Validation of structural-based virtual screening protocols with the PDB Code 3G0B and prediction of the activity of Tinospora crispa compounds as inhibitors of dipeptidyl-peptidase-IV | ru |
| dc.type | Article | ru |
| Appears in Collections: | Vol. 8, № 1
|
